A phase I/II trial of BNC105P with everolimus in metastatic renal cell carcinoma (mRCC.

Publication Type:

Journal Article

Source:

Clinical cancer research : an official journal of the American Association for Cancer Research, Volume 21, Issue 15, p.3420-7 (2015)

Keywords:

Specimen Processing Core Facility

Abstract:

BNC105P inhibits tubulin polymerization, and preclinical studies suggest possible synergy with everolimus. In this phase I/II study, efficacy and safety of the combination were explored in patients with metastatic renal cell carcinoma (mRCC).